| |
|
|
|
|
|
 |
| |
|
»ï¼º¿¡¸®½º·Î¸¶À̽ÅÁ¤ ERYTHROMYCIN SAMSUNG TAB.
|
|
Àü¹®ÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
(erythromycin; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ½É»ç»ç·Ê |
¸¸¼ºÈ£Èí±âÁúȯ¿¡ Àå±â Åõ¿©µÈ macrolide °è¿ Á¦Á¦¿¡ ´ëÇÏ¿©
¡á ½ÉÀÇ¹è°æ
ÇöÀç macrolide°è¿(clarithromycin, erythromycin, roxithromycin, azithromycin) Á¦Á¦¸¦ ¸¸¼ºÈ£Èí±â Áúȯ¿¡¼ Àå±â Åõ¿©ÇÏ´Â »ç·Ê°¡ ¹ß»ýÇϰí ÀÖ¾î ÀÌÀÇ ÀÇÇÐÀû Ÿ´ç¼º¿¡ ´ëÇØ ½ÉÀÇÇÔ.
¡á Âü°í
¡Û Clarithromycin °æ±¸Á¦ (ǰ¸í:Ŭ·¡¸®½ÃµåÇʸ§ÄÚÆÃÁ¤250mg µî) ÀÎÁ¤±âÁØ (º¸°Çº¹ÁöºÎ°í½Ã Á¦2010-20È£, 2010.05.01)
¡Û ½ÄǰÀǾàǰ¾ÈÀüû Çã°¡»çÇ×
¡Û ±èÁ¾¼±. À̺ñÀÎÈİúÇÐ(´ëÇÑÀ̺ñÀÎÈİúÇÐȸ Æí). ÀÏÁ¶°¢. 2002.
¡Û ´ëÇѰ¨¿°ÇÐȸ. Ç×»ýÁ¦ÀÇ ±æÀâÀÌ, Á¦3ÆÇ. 2008.
¡Û ±è¿µÈ¯ ¿Ü. ±â°üÁöÈ®ÀåÁõ¿¡¼ ErythromycinÀÇ ¼Ò·® Àå±âÅõ¿© È¿°ú. °áÇÙ ¹× È£Èí±âÁúȯ
¡á ½ÉÀdz»¿ë
Macrolide°è¿(clarithromycin, erythromycin, roxithromycin, azithromycin)Á¦Á¦°¡ ¸¸¼ºÈ£Èí±â Áúȯ¿¡¼ Àå±â Åõ¿©µÇ´Â »ç·Ê°¡ ¹ß»ýÇϰí ÀÌ¿Í °ü·ÃÇÑ ³í¹®µéÀÌ ³ª¿À°í ÀÖÀ¸³ª, Àú¿ë·® Àå±â¿ä¹ýÀÇ °æ¿ì Ç×»ýÁ¦ ³»¼º À¯¹ß µîÀÇ ½É°¢ÇÑ ¹®Á¦¸¦ ¾ß±âÇÒ ¼ö ÀÖ´Â Á¡À» °í·ÁÇØº¼ ¶§ chronic sinusitis, bronchiectasis, COPD µî¿¡¼ macrolide°è Á¦Á¦ÀÇ Àå±â»ç¿ë¿¡ ´ëÇÑ Ä¡·áÈ¿°ú ¹× ÀÇÇÐÀû Ÿ´ç¼º¿¡ ´ëÇÏ¿© ü°èÀû ¹®Çå°íÂûÀÌ ÇÊ¿äÇÏ´Ù´Â ÀǰßÀÌ Á¦±âµÇ¾î(¡®08.3.28 ³»°ú¥³ºÐÀ§) EBH¿¡ ¹®Çå°íÂûÀ» ¿äûÇÏ¿© ³íÀÇÇÑ °á°ú
¡®¸¸¼ºÈ£Èí±âÁúȯ¿¡ Àú¿ë·® Àå±â Åõ¿©(low-dose, long-term therapy)µÈ macrolides°è¿ Á¦Á¦ÀÇ ÀÓ»óÀû À¯¿ë¼º ¹× ¾ÈÀü¼ºÀ» ÀÔÁõÇÒ ¸¸ÇÑ ±Ù°Å´Â ÇöÀç±îÁö ÃæºÐÇÏÁö ¾Ê´Ù°í ÆÇ´ÜµÈ´Ù.¡¯´Â EBH º¸°í¼¸¦ ÂüÁ¶½Ã Â÷ÈÄ macrolides°è Á¦Á¦ÀÇ Àú¿ë·® Àå±â Åõ¿©·Î ÀÎÇÑ ³»¼º±Õ ÃâÇöÀ̳ª ±Õ±³´ëÇö»ó µî ¾ÈÀü¼º ¹× À¯È¿¼º¿¡ ´ëÇÑ ÃæºÐÇÑ ±Ù°Å°¡ È®¸³µÉ ¶§±îÁö ¸¸¼ºÈ£Èí±âÁúȯ¿¡ macrolides°è¿ Á¦Á¦ÀÇ Àú¿ë·® Àå±âÅõ¿©´Â ÇöÇà´ë·Î ½Ä¾àû Çã°¡»çÇ×(¿ë¹ý¿ë·®) µîÀ» ÃʰúÇÑ °æ¿ì·Î º¸¾Æ ÀÎÁ¤ÇÏÁö ¾Æ´ÏÇÔ.
[2010.06.07 Áø·á½É»çÆò°¡À§¿øÈ¸]
|
| DUR °ü·Ã °í½Ã |
[º´¿ë¿¬·É±Ý±â ÀǾàǰ / ÀӺαݱâ ÀǾàǰ / ºñ¿ëÈ¿°úÀû ÇÔ·® ÀǾàǰ / ¾ÈÀü¼º °ü·Ã ±Þ¿©ÁßÁö ÀǾàǰ]
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Description |
Erythromycin¿¡ ´ëÇÑ Description Á¤º¸ Erythromycin is a bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. [PubChem]
|
| Dosage Form |
Erythromycin¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule, coated OralLiquid DentalLiquid OralOintment OphthalmicPowder IntravenousPowder OralPowder, for solution IntravenousPowder, for solution OralPowder, for suspension OralSuspension OralTablet Oral
|
| Drug Category |
Erythromycin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial Agents
|
| Smiles String Canonical |
Erythromycin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O
|
| Smiles String Isomeric |
Erythromycin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
|
| InChI Identifier |
Erythromycin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
|
| Chemical IUPAC Name |
Erythromycin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
|
| Drug-Induced Toxicity Related Proteins |
ERYTHROMYCIN ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Misshapen-like kinase(Mink) Drug:Erythromycin Toxicity:torsade de pointes. [¹Ù·Î°¡±â] Replated Protein:Potassium voltage-gated channel subfamily KQT member 1 (KvLQT1) Drug:Erythromycin Toxicity:torsade de pointes. [¹Ù·Î°¡±â] Replated Protein:Intercellular adhesion molecule 1 Drug:erythromycin Toxicity:pathogenesis of infusion phlebitis. [¹Ù·Î°¡±â] Replated Protein:HERG Drug:Erythromycin Toxicity:torsade de pointes. [¹Ù·Î°¡±â] Replated Protein:Alanine aminotransferase Drug:erythromycin Toxicity:adverse gastrointestinal effects. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2018-02-26
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|